Zacks Investment Research
02 Jul 2026, 15:51 UTC · 2h ago
AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
02 Jul 2026, 15:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
AtaiBeckley's lead candidate BPL-003 is planned to begin two pivotal phase III studies for treatment-resistant depression in the second quarter of 2026. — The transition to pivotal late-stage trials is the most significant value-driver for clinical-stage biotech companies and represents a major binary risk/reward event.
+0.60The FDA has granted Breakthrough Therapy designation to BPL-003 for treatment-resistant depression. — This designation suggests a faster path to approval and a higher likelihood of clinical success, though it is less impactful than the actual start of Phase III trials.
+0.30Top-line data for VLS-01, an oral transmucosal film formulation for depression, is expected in the second half of 2026. — This provides a secondary catalyst and diversifies the pipeline risk, though Phase II data is generally less market-moving than Phase III.
+0.20Continue reading
6 related stories
Top 1 mover · tap to explore
AtaiBeckley currently has no approved products and is highly exposed to the execution of its clinical trials. — The lack of commercial revenue increases the company's risk profile and dependency on external funding or successful trial outcomes.
-0.20Which stocks this story touches
The company is entering a catalyst-heavy period with positive mid-stage results and FDA Breakthrough Therapy designation for its lead program.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
24/7 Wall Street
4h ago
